Does MIDOSTAURIN Cause Second primary malignancy? 17 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 17 reports of Second primary malignancy have been filed in association with MIDOSTAURIN (RYDAPT). This represents 0.6% of all adverse event reports for MIDOSTAURIN.
17
Reports of Second primary malignancy with MIDOSTAURIN
0.6%
of all MIDOSTAURIN reports
3
Deaths
3
Hospitalizations
How Dangerous Is Second primary malignancy From MIDOSTAURIN?
Of the 17 reports, 3 (17.6%) resulted in death, 3 (17.6%) required hospitalization, and 2 (11.8%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MIDOSTAURIN. However, 17 reports have been filed with the FAERS database.
What Other Side Effects Does MIDOSTAURIN Cause?
Death (397)
Nausea (252)
Febrile neutropenia (223)
Diarrhoea (194)
Pyrexia (188)
Acute myeloid leukaemia recurrent (171)
Pancytopenia (152)
Vomiting (152)
Drug ineffective (151)
Thrombocytopenia (140)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which MIDOSTAURIN Alternatives Have Lower Second primary malignancy Risk?
MIDOSTAURIN vs MIFEPRISTONE
MIDOSTAURIN vs MIGALASTAT
MIDOSTAURIN vs MIGLITOL
MIDOSTAURIN vs MIGLUSTAT
MIDOSTAURIN vs MILNACIPRAN